Toll Free: 1-888-928-9744

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

Published: Aug 24, 2016 | Pages: 267 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016', provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Wet (Neovascular / Exudative) Macular Degeneration Overview 10 Therapeutics Development 11 Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 11 Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 12 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 19 Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 25 Aciont Inc. 25 Adverum Biotechnologies, Inc. 26 Allergan Plc 27 Alteogen Inc. 28 Amakem NV 29 Ampio Pharmaceuticals, Inc. 30 Apellis Pharmaceuticals, Inc. 31 Apexigen, Inc. 32 Applied Genetic Technologies Corporation 33 Benitec Biopharma Limited 34 Boehringer Ingelheim GmbH 35 Cell Medica Limited 36 Charlesson LLC. 37 Cipla Ltd. 38 Clanotech AB 39 Clearside BioMedical, Inc. 40 Clonz Biotech Private Limited 41 Coherus BioSciences, Inc. 42 Daiichi Sankyo Company, Limited 43 Diffusion Pharmaceuticals Inc. 44 Eleven Biotherapeutics Inc. 45 Exonate Limited 46 F. Hoffmann-La Roche Ltd. 47 Formycon AG 48 Graybug Vision Inc 49 GTx, Inc. 50 iCo Therapeutics Inc. 51 Icon Bioscience, Inc. 52 Iconic Therapeutics, Inc. 53 Kala Pharmaceuticals, Inc. 54 Kodiak Sciences Inc. 55 Mabion SA 56 MeiraGTx Limited 57 Mitotech S.A. 58 Ocular Therapeutix, Inc. 59 Ohr Pharmaceutical Inc. 60 Ophthotech Corp. 61 Oxford BioMedica Plc 62 PanOptica, Inc. 63 Pfenex Inc. 64 Pfizer Inc. 65 pSivida Corp. 66 Regeneron Pharmaceuticals Inc 67 RegenxBio Inc. 68 RXi Pharmaceuticals Corporation 69 Santen Pharmaceutical Co., Ltd. 70 Sanwa Kagaku Kenkyusho Co., Ltd. 71 TRACON Pharmaceuticals, Inc. 72 TWi Pharmaceuticals, Inc. 73 Tyrogenex, Inc. 74 Xbrane Biopharma AB 75 Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 76 Assessment by Monotherapy Products 76 Assessment by Combination Products 77 Assessment by Target 78 Assessment by Mechanism of Action 81 Assessment by Route of Administration 85 Assessment by Molecule Type 87 Drug Profiles 89 (aflibercept + nesvacumab) - Drug Profile 89 (aflibercept + rinucumab) - Drug Profile 90 A-006 - Drug Profile 91 abicipar pegol - Drug Profile 92 AC-301 - Drug Profile 95 ACX-107 - Drug Profile 96 aflibercept - Drug Profile 97 aflibercept biosimilar - Drug Profile 106 aflibercept biosimilar - Drug Profile 107 AGN-151200 - Drug Profile 108 ALG-1001 - Drug Profile 110 AMA-0428 - Drug Profile 113 APL-2 - Drug Profile 114 APX-003 - Drug Profile 116 APX-3330 - Drug Profile 117 AVA-101 - Drug Profile 119 AVA-201 - Drug Profile 122 avacincaptad pegol sodium - Drug Profile 123 axitinib - Drug Profile 125 AXT-108 - Drug Profile 127 bertilimumab - Drug Profile 128 Beta-LGND2 - Drug Profile 132 BI-144807 - Drug Profile 134 brolucizumab - Drug Profile 135 C-16Y - Drug Profile 137 CBT-128 - Drug Profile 138 CLT-005 - Drug Profile 139 CLT-28643 - Drug Profile 140 cyclosporine - Drug Profile 141 DA-3131 - Drug Profile 142 danazol - Drug Profile 143 DE-120 - Drug Profile 147 DNX-214 - Drug Profile 148 Doxarubicin Pegylated - Drug Profile 149 Drug for Age Related Macular Degeneration - Drug Profile 150 DS-7080 - Drug Profile 151 ENV-1305 - Drug Profile 152 GB-101 - Drug Profile 153 Gene Therapy 1 for Wet Age-Related Macular Degeneration - Drug Profile 154 Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile 155 hI-con1 - Drug Profile 156 IVMED-50 - Drug Profile 158 IVMED-55 - Drug Profile 159 K-106 - Drug Profile 160 KSI-201 - Drug Profile 161 LHA-510 - Drug Profile 162 Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 163 OCU-200 - Drug Profile 164 OLX-301 - Drug Profile 165 ONL-1204 - Drug Profile 166 OPT-302 - Drug Profile 167 OXB-201 - Drug Profile 171 PAN-90806 - Drug Profile 173 pegpleranib sodium - Drug Profile 175 PF-05206388 - Drug Profile 178 PF-655 - Drug Profile 180 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 182 Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 184 ranibizumab - Drug Profile 185 ranibizumab biosimilar - Drug Profile 191 ranibizumab biosimilar - Drug Profile 192 ranibizumab biosimilar - Drug Profile 193 ranibizumab biosimilar - Drug Profile 195 ranibizumab biosimilar - Drug Profile 196 ranibizumab biosimilar - Drug Profile 197 ranibizumab biosimilar - Drug Profile 198 Recombinant Protein for Age Related Macular Degeneration - Drug Profile 199 Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 200 RES-529 - Drug Profile 201 RG-7716 - Drug Profile 205 RGX-314 - Drug Profile 206 RXI-109 - Drug Profile 208 SK-1011 - Drug Profile 214 Small Molecule for Wet AMD and Dry AMD - Drug Profile 215 Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 216 Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration - Drug Profile 217 SPHINX-31 - Drug Profile 218 squalamine lactate - Drug Profile 219 sunitinib malate - Drug Profile 227 Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration - Drug Profile 229 TRC-105 - Drug Profile 230 triamcinolone acetonide - Drug Profile 238 TT-211 - Drug Profile 239 TT-231 - Drug Profile 240 X-82 - Drug Profile 241 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 244 Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 248 Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 249 Featured News & Press Releases 249 Appendix 259 Methodology 259 Coverage 259 Secondary Research 259 Primary Research 259 Expert Panel Validation 259 Contact Us 259 Disclaimer 260
List of Tables
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016 18 Number of Products under Development by Companies, H2 2016 19 Number of Products under Development by Companies, H2 2016 (Contd..1) 20 Number of Products under Development by Companies, H2 2016 (Contd..2) 21 Number of Products under Development by Companies, H2 2016 (Contd..3) 22 Comparative Analysis by Late Stage Development, H2 2016 23 Comparative Analysis by Clinical Stage Development, H2 2016 24 Comparative Analysis by Early Stage Development, H2 2016 25 Products under Development by Companies, H2 2016 26 Products under Development by Companies, H2 2016 (Contd..1) 27 Products under Development by Companies, H2 2016 (Contd..2) 28 Products under Development by Companies, H2 2016 (Contd..3) 29 Products under Development by Companies, H2 2016 (Contd..4) 30 Products under Development by Companies, H2 2016 (Contd..5) 31 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Aciont Inc., H2 2016 32 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Adverum Biotechnologies, Inc., H2 2016 33 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan Plc, H2 2016 34 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Alteogen Inc., H2 2016 35 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H2 2016 36 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 37 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H2 2016 38 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apexigen, Inc., H2 2016 39 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H2 2016 40 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2016 41 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2016 42 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Cell Medica Limited, H2 2016 43 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H2 2016 44 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Cipla Ltd., H2 2016 45 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clanotech AB, H2 2016 46 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H2 2016 47 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clonz Biotech Private Limited, H2 2016 48 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Coherus BioSciences, Inc., H2 2016 49 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 50 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 51 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H2 2016 52 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Exonate Limited, H2 2016 53 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 54 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Formycon AG, H2 2016 55 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Graybug Vision Inc, H2 2016 56 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GTx, Inc., H2 2016 57 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2016 58 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2016 59 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Iconic Therapeutics, Inc., H2 2016 60 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 61 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kodiak Sciences Inc., H2 2016 62 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mabion SA, H2 2016 63 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by MeiraGTx Limited, H2 2016 64 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mitotech S.A., H2 2016 65 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H2 2016 66 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H2 2016 67 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2016 68 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica Plc, H2 2016 69 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H2 2016 70 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H2 2016 71 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H2 2016 72 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H2 2016 73 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 74 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RegenxBio Inc., H2 2016 75 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 76 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 77 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 78 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016 79 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H2 2016 80 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tyrogenex, Inc., H2 2016 81 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Xbrane Biopharma AB, H2 2016 82 Assessment by Monotherapy Products, H2 2016 83 Assessment by Combination Products, H2 2016 84 Number of Products by Stage and Target, H2 2016 86 Number of Products by Stage and Mechanism of Action, H2 2016 89 Number of Products by Stage and Route of Administration, H2 2016 93 Number of Products by Stage and Molecule Type, H2 2016 95 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H2 2016 251 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..1), H2 2016 252 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..2), H2 2016 253 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..3), H2 2016 254 Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H2 2016 255


List of Figures
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016 18 Number of Products under Development by Companies, H2 2016 19 Comparative Analysis by Late Stage Development, H2 2016 23 Comparative Analysis by Clinical Stage Development, H2 2016 24 Comparative Analysis by Early Stage Products, H2 2016 25 Assessment by Monotherapy Products, H2 2016 83 Number of Products by Top 10 Targets, H2 2016 85 Number of Products by Stage and Top 10 Targets, H2 2016 85 Number of Products by Top 10 Mechanism of Actions, H2 2016 88 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 88 Number of Products by Top 10 Routes of Administration, H2 2016 92 Number of Products by Stage and Top 10 Routes of Administration, H2 2016 92 Number of Products by Top 10 Molecule Types, H2 2016 94 Number of Products by Stage and Top 10 Molecule Types, H2 2016 94

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable gover

Read More...

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...

Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiency

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify